Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience

American Journal of Hematology

Volumn 84, Issue 7, 2009, Pages 408-413

  Vemulapalli, Sushma ^a   Chintala, Lakshmi ^a   Tsimberidou, Apostolia Maria ^a   Dhillon, Navjot ^a   Lei, Xiudong ^a   Hong, David ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER SURVIVAL; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PANCREATIC NEOPLASMS; PLATELET COUNT; PROGNOSIS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 67649739493     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21423     Document Type: Article

References (30)

1. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505. (Pubitemid 350232226)
2. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet 1998;351:1077-1080. (Pubitemid 28163410)
3. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133.
4. Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia (New York, NY) 2002;4: 465-473. (Pubitemid 35417069)
5. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med 2002;162:1245-1248. (Pubitemid 34595030)
6. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000;160:809-815. (Pubitemid 30165241)
7. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634. (Pubitemid 46680709)
8. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park, NY) 2003;17:126-135, 139; discussion 139-144.
9. Ottinger H, Belka C, Kozole G, et al. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: Incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186-194.
10. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593. (Pubitemid 28144815)
11. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999;25:137-145. (Pubitemid 29227142)
12. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: High incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 2005;23:2574-2576. (Pubitemid 47053842)
13. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675. (Pubitemid 46594061)
14. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992;305:567-574.
15. Arcelus JI, Candocia S, Traverso CI, et al. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991;17 (Suppl 3):313-318.
16. Lutz L. Venous thromboembolism in internal medicine: Risk assessment and pharmaceutical prophylaxis. Die Med Welt 2002;53:231-234. (Pubitemid 34982622)
17. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: Validation of a thrombosis risk score. J Thromb Haemost 2004; 2:2156-2161. (Pubitemid 40185776)
18. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111: 4902-4907.
19. Prandoni P. Cancer and thromboembolic disease: How important is the risk of thrombosis? Cancer Treat Rev 2002;28:133-136.
20. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129. (Pubitemid 46218703)
21. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490. (Pubitemid 46630468)
22. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002;87:575-579. (Pubitemid 34302943)
23. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13:2870-2875. (Pubitemid 46849560)
24. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327. (Pubitemid 24286478)
25. Kranenburg O, Gebbink MF, Voest EE. Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta 2004;1654:23-37. (Pubitemid 38230929)
26. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: An analysis of 129 cases. Am J Hematol 1985;20:365-372. (Pubitemid 16222303)
27. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
28. Rinder HM, Schuster JE, Rinder CS, et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood 1998;91:1288-1294. (Pubitemid 28086882)
29. Estrov Z, Talpaz M, Mavligit G, et al. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995;98:551-558.
30. Arkenau HT, Olmos D, Ang JE, et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? Eur J Cancer 2008;44:1536-1540.